Without knowing why did it happened, I don't have clear opinion. But it could be either negative or neutral. I don't see how it can be positive. Hope, it is not clinical data related.
Recent BDTX News
- Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting • GlobeNewswire Inc. • 04/21/2026 02:40:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/16/2026 08:12:07 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/16/2026 08:03:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 08:02:04 PM
- Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/16/2026 08:01:00 PM
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 03/02/2026 09:01:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 09:09:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:05:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2026 09:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2025 09:33:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2025 01:20:44 PM
- Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM • GlobeNewswire Inc. • 12/03/2025 12:01:00 PM
- Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update • GlobeNewswire Inc. • 12/02/2025 09:01:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/13/2025 10:20:14 PM
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 11/06/2025 09:01:00 PM
- Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/06/2025 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2025 12:12:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2025 12:01:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/22/2025 09:45:37 PM
- Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/07/2025 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2025 11:04:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2025 11:01:46 AM
- Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/29/2025 12:00:00 PM
